1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

BioMarin’s Orphan Drug Clinical Strategy Is Rooted In Natural History

 
• By Bridget Silverman

BioMarin has emerged at the forefront of orphan drug development by grounding its clinical trials in natural history studies. The specialty firm’s recent investor day highlighted how clinical trials in ultra-orphan disorders are informed by efforts to quantify the clinical course of often poorly-understood conditions to determine appropriate endpoints and dosing strategies.

The lack of therapeutic options in many orphan diseases makes them an appealing prospect for specialty drug developers looking for the regulatory flexibility and market benefits that accrue to the first therapies for serious unmet medical needs, but BioMarin Pharmaceutical Inc.’s recent investor day highlighted the extra effort that orphan drug developers must put in to elucidate the natural history of often poorly-understood rare diseases in order to design clinical trials and justify clinical endpoints.

Orphan drug development is a hot field right now. Novel orphan drug approvals reached their highest count ever in 2014 ([A#06150101023]). Merger and acquisition activity among orphan boutiques is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

Drug, Biologic Policy Staff Return To US FDA, As RIF Process Hangs In Legal Limbo

 
• By Sarah Karlin-Smith

The FDA employees with reduction-in-force notice rescissions include some who work on user fee negotiations, but staff still subject to RIFs will not officially separate from the agency this week due to ongoing legal challenges.

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.

More from North America

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

US FDA’s ‘Good Reputation’ For Science May Mean Loper Bright Not ‘Cataclysmic,’ Attorney Says

 
• By Malcolm Spicer

Bridget Dooling, a law school professor who reviewed draft regulations from the FDA and other agencies as an OMB attorney, said prior federal court decisions suggest judges typically defer to agency decisions based in science.